1 EXHIBIT 11 HEMISPHERx BIOPHARMA, INC. STATEMENTS REGARDING COMPUTATION OF PROFORMA NET LOSS PER SHARE For the three months ended March 31, 1995 and 1996 Three Months Ended March 31, (unaudited) -------------------------------------- 1995 1996 ---- ---- NET LOSS PER SHARE (PROFORMA) Net Loss: $ (586,647) $ (671,759) ======= ======= Shares: Weighted average number of common shares outstanding during the period 7,219,710 15,581,592 Incremental shares representing: Options and warrants issued within one year period prior to an initial public offering 3,858,538 - Conversion of Preferred Stock to Common Stock 1,935,926 - ---------- ---------- Weighted average number of shares used in calculating proforma net loss per share 13,014,174 15,581,592 ========== ========== Net loss per share $ (.05) $ (.04) === === 13